IN THE UNITED STATES DISTRICT COURT
THE DISTRICT OF DELAWARE SALIX PHARMACEUTICALS, INC. and DR. F ALK PHARMA GmbH, Plaintiffs,
LUPIN LIMITED and LUPIN PHARMACEUTICALS, INC., Defendants.
Civil Action No. 12-1104-GMS
ORDER CONSTRUING THE TERMS OF
PATENT NOS. 6,551,620; 7,547,451; 8,337,886; and 8,496,965
After having considered the submissions
the parties, and hearing oral argument on the matter, IT
HEREBY ORDERED, ADJUDGED, and DECREED that, as used in the asserted claims
U.S. Patent Nos. 6,551,620 ( the '620 patent ), 7,547,451 ( the '451 patent ), 8,337,886 ( the '886 patent ), and 8,496,965 ( the '965 patent ):
The court adopts the parties' proposed construction for the term
to mean small, free-flowing spherical or semi-spherical particles formed from an agglomeration
bulk drugs and excipients using wet mass extrusion/ spheronization.
The plaintiffs Salix Pharmaceuticals, Inc. ( Salix ) and Dr. Falk Pharma GmbH ( Dr. Falk ) (collectively, plaintiffs ) and the defendants Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin ) agreed upon the construction
the term pellet
the Joint Claim Chart. (D.I. 84-1.)
a genuine dispute, the court will not construe this term.
Micro International Ltd.
Beyond Innovation Technology
F.3d 1351, 1360 (Fed. Cir. 2008);
US. Surgical Corp.
F .3d 1554, 1568 (Fed. Cir. 1997).
Case 1:12-cv-01104-GMS Document 118 Filed 12/17/13 Page 1 of 15 PageID #: 1134